The 23 references in paper M. RYBALOV A., I. De YONG Ya, A. BREUSMA J., S. AL-SHUKRI H., S. BOROVETS Yu., М. РЫБАЛОВ А., И. ДЕ ЙОНГ Я., А. БРЕУСМА Й., С. АЛЬ-ШУКРИ Х., С. БОРОВЕЦ Ю. (2011) “РОЛЬ ПРОСТАТОСПЕЦИФИЧЕСКОГО АНТИГЕНА И ЕГО КИНЕТИЧЕСКИХ ХАРАКТЕРИСТИК ПРИ ОТБОРЕ БОЛЬНЫХ ДЛЯ КОНТРОЛЬНОЙ 11C-ХОЛИН ПОЗИТРОННО-ЭМИССИОННОЙ/ КОМПЬЮТЕРНОЙ ТОМОГРАФИИ ПОСЛЕ РАДИОТЕРАПИИ ИЛИ РАДИКАЛЬНОЙ ПРОСТАТЭКТОМИИ // ROLE OF PROSTATE SPECIFIC ANTIGEN AND ITS KINETIC CHARACTERISTICS AT PАTIENT SELECTION FOR CONTROL 11C-CHOLIN POSITRON-EMISSION/COMPUTERIZED TOMOGRAPHY AFTER RADIOTHERAPY AND RADICAL PROSTATECTOMY” / spz:neicon:nefr:y:2011:i:4:p:55-61

1
Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Longterm biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555–565
(check this in PDF content)
2
Zagars GK. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol 1994; 152: 1786-1791
(check this in PDF content)
3
Breeuwsma AJ, Pruim J, Van Den Bergh ACM et al. Detection of local, regional and distant recurrence in patients with PSA relapse after external beam radiotherapy using 11Ccholine positron emission tomography. Int J Radiat Oncol Biol Phys 2010; 77: 160-164
(check this in PDF content)
4
Maffezzini M, Bossi A, Collette L. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol 2007; 51: 605–613
(check this in PDF content)
5
Palma D, Tyldesley S, Pickles T. Prostate Cohort Outcomes Initiative. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy. Cancer 2008; 112: 1941– 1948
(check this in PDF content)
6
Petit JH, Chen MH, Loffredo M, Sussman B, Renshaw AA, D’Amico AV. Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer. Cancer 2006; 107: 2180– 2185
(check this in PDF content)
7
Castellucci P, Fuccio C, Nanni C et al. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009; 50: 1394-1400
(check this in PDF content)
8
Giovacchini G, Picchio M, Scattoni V et al. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010; 37: 11061116
(check this in PDF content)
9
Fitzpatrick JM, Banu E, Oudard S. Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int 2009; 103: 578-587
(check this in PDF content)
10
Picchio M, Messa C, Landoni C et al. Value of 11C choline-positron emission tomography for restaging prostate cancer: a comparison with 18F fluorodeoxyglucose-positron emission tomography. J Urol 2003; 169: 1337–1340
(check this in PDF content)
11
Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003; 44: 32–38
(check this in PDF content)
12
Rinnab L, Mottaghy FM, Blumstein NM et al. Evaluation of 11C-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007; 100: 786– 793
(check this in PDF content)
13
Krause BJ, Souvatzoglou M, Tuncel M et al. The detection rate of [(11)C]choline-PET/CT depends on the serum PSAvalue in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35: 18–23
(check this in PDF content)
14
Tsukamoto E, Ochi S. PET/CT today: system and its impact on cancer diagnosis. Ann Nucl Med 2006; 20: 255-267
(check this in PDF content)
15
Townsend DW. Dual-modality imaging: combining anatomy and function. J Nucl Med 2008; 49: 938-955
(check this in PDF content)
16
Consensus statement. Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37: 1035-1041
(check this in PDF content)
17
Hara T. 11C-choline and 2-deoxy-2-[18F]fluoro-Dglucose in tumor imaging with positron emission tomography. Mol Imaging Biol 2002; 4: 267-273
(check this in PDF content)
18
Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostatespecific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993; 71: 20312040
(check this in PDF content)
19
Connolly D, Black A, Murray LJ, Napolitano G, Gavin A, Keane PF. Methods of calculating prostate-specific antigen velocity. Eur Urol 2007; 52: 1044– 1051
(check this in PDF content)
20
Stamey TA, Kabalin JN, McNeal JE et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141: 1076-1083
(check this in PDF content)
21
Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol 2002; 167: 103-111
(check this in PDF content)
22
Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003; 44: 331-335
(check this in PDF content)
23
Scattoni V, Picchio M, Suardi N et al. Detection of lymphnode metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007; 52: 423-429
(check this in PDF content)